# Study-Type Specific Checklists (v0.2)

## Overview
연구 유형에 따른 reporting guideline 체크리스트입니다. 제출 전 해당 연구 유형의 체크리스트를 완료하세요.

| Study Type | Checklist | Use When |
|------------|-----------|----------|
| Cohort, Case-control, Cross-sectional | STROBE | 관찰 연구 |
| Randomized Controlled Trial | CONSORT | 무작위 대조 시험 |
| Systematic Review / Meta-analysis | PRISMA | 체계적 문헌고찰 |
| Case Report | CARE | 증례 보고 |
| Diagnostic Accuracy | STARD | 진단 검사 연구 |
| Clinical Trial Protocol | SPIRIT | 프로토콜 논문 |
| Quality Improvement | SQUIRE | QI 연구 |

---

## STROBE Checklist (Observational Studies)
*Cohort, Case-control, Cross-sectional studies*

### Title and Abstract
| # | Item | Location | Done |
|---|------|----------|------|
| 1a | Study design in title or abstract | Title/Abstract | [ ] |
| 1b | Structured abstract with key elements | Abstract | [ ] |

### Introduction
| # | Item | Location | Done |
|---|------|----------|------|
| 2 | Scientific background and rationale | Introduction | [ ] |
| 3 | Specific objectives, including pre-specified hypotheses | Introduction | [ ] |

### Methods
| # | Item | Location | Done |
|---|------|----------|------|
| 4 | Study design presented early | Methods | [ ] |
| 5 | Setting (locations, dates, periods of recruitment/follow-up) | Methods | [ ] |
| 6a | Eligibility criteria | Methods | [ ] |
| 6b | Sources and methods of selection | Methods | [ ] |
| 7 | Outcomes, exposures, predictors clearly defined | Methods | [ ] |
| 8 | Data sources and measurement methods | Methods | [ ] |
| 9 | Efforts to address potential bias | Methods | [ ] |
| 10 | How study size was determined | Methods | [ ] |
| 11 | How quantitative variables were handled | Methods | [ ] |
| 12a | All statistical methods described | Methods | [ ] |
| 12b | Methods for subgroups and interactions | Methods | [ ] |
| 12c | How missing data was addressed | Methods | [ ] |
| 12d | Loss to follow-up addressed (cohort) | Methods | [ ] |
| 12e | Sensitivity analyses | Methods | [ ] |

### Results
| # | Item | Location | Done |
|---|------|----------|------|
| 13a | Numbers at each stage (flow diagram recommended) | Results | [ ] |
| 13b | Reasons for non-participation | Results | [ ] |
| 14a | Characteristics of participants | Results/Table 1 | [ ] |
| 14b | Missing data indicated | Results/Tables | [ ] |
| 15 | Outcome data | Results | [ ] |
| 16a | Unadjusted estimates with CI/p-values | Results | [ ] |
| 16b | Adjusted estimates with CI/p-values | Results | [ ] |
| 16c | Relative and absolute risk (if applicable) | Results | [ ] |
| 17 | Other analyses (subgroup, sensitivity) | Results | [ ] |

### Discussion
| # | Item | Location | Done |
|---|------|----------|------|
| 18 | Key results summarized | Discussion | [ ] |
| 19 | Limitations discussed | Discussion | [ ] |
| 20 | Cautious interpretation | Discussion | [ ] |
| 21 | Generalizability | Discussion | [ ] |

### Other
| # | Item | Location | Done |
|---|------|----------|------|
| 22 | Funding source | Title page/Acknowledgments | [ ] |

---

## CONSORT Checklist (Randomized Controlled Trials)

### Title and Abstract
| # | Item | Location | Done |
|---|------|----------|------|
| 1a | "Randomized" in title | Title | [ ] |
| 1b | Structured abstract (design, methods, results, conclusions) | Abstract | [ ] |

### Introduction
| # | Item | Location | Done |
|---|------|----------|------|
| 2a | Scientific background and rationale | Introduction | [ ] |
| 2b | Specific objectives or hypotheses | Introduction | [ ] |

### Methods
| # | Item | Location | Done |
|---|------|----------|------|
| 3a | Trial design (parallel, factorial, etc.) with allocation ratio | Methods | [ ] |
| 3b | Important changes after trial start | Methods | [ ] |
| 4a | Eligibility criteria | Methods | [ ] |
| 4b | Settings and locations | Methods | [ ] |
| 5 | Interventions described with sufficient detail | Methods | [ ] |
| 6a | Pre-specified primary and secondary outcomes | Methods | [ ] |
| 6b | Any changes to outcomes after start | Methods | [ ] |
| 7a | How sample size was determined | Methods | [ ] |
| 7b | Interim analyses explanation (if any) | Methods | [ ] |
| 8a | Sequence generation method | Methods | [ ] |
| 8b | Type of randomization (block, stratified, etc.) | Methods | [ ] |
| 9 | Allocation concealment mechanism | Methods | [ ] |
| 10 | Who generated sequence, enrolled, assigned | Methods | [ ] |
| 11a | Who was blinded (participants, providers, assessors) | Methods | [ ] |
| 11b | Description of similarity of interventions | Methods | [ ] |
| 12a | Statistical methods for primary and secondary outcomes | Methods | [ ] |
| 12b | Methods for additional analyses (subgroup, adjusted) | Methods | [ ] |

### Results
| # | Item | Location | Done |
|---|------|----------|------|
| 13a | Flow diagram with numbers | Results/Figure | [ ] |
| 13b | Losses and exclusions with reasons | Results | [ ] |
| 14a | Recruitment dates | Results | [ ] |
| 14b | Why trial ended or stopped | Results | [ ] |
| 15 | Baseline demographic table | Results/Table 1 | [ ] |
| 16 | Numbers analyzed in each group (ITT) | Results | [ ] |
| 17a | Primary and secondary outcomes with effect size and CI | Results | [ ] |
| 17b | Binary outcomes: absolute and relative effect sizes | Results | [ ] |
| 18 | All important harms or unintended effects | Results | [ ] |

### Discussion
| # | Item | Location | Done |
|---|------|----------|------|
| 19 | Trial limitations | Discussion | [ ] |
| 20 | Generalizability | Discussion | [ ] |
| 21 | Interpretation consistent with results | Discussion | [ ] |

### Other
| # | Item | Location | Done |
|---|------|----------|------|
| 22 | Registration number and name of registry | Methods/Abstract | [ ] |
| 23 | Where full protocol can be accessed | Methods | [ ] |
| 24 | Funding sources | Acknowledgments | [ ] |
| 25 | Role of funders | Acknowledgments | [ ] |

---

## PRISMA Checklist (Systematic Reviews & Meta-analyses)

### Title
| # | Item | Location | Done |
|---|------|----------|------|
| 1 | "Systematic review" and/or "meta-analysis" in title | Title | [ ] |

### Abstract
| # | Item | Location | Done |
|---|------|----------|------|
| 2 | Structured summary (background, objectives, methods, results, conclusions) | Abstract | [ ] |

### Introduction
| # | Item | Location | Done |
|---|------|----------|------|
| 3 | Rationale for review | Introduction | [ ] |
| 4 | Explicit PICO question | Introduction | [ ] |

### Methods
| # | Item | Location | Done |
|---|------|----------|------|
| 5 | Protocol registration (PROSPERO number) | Methods | [ ] |
| 6 | Eligibility criteria (PICOS) | Methods | [ ] |
| 7 | Information sources (databases, dates, contact with authors) | Methods | [ ] |
| 8 | Full search strategy for at least one database | Methods/Appendix | [ ] |
| 9 | Study selection process | Methods | [ ] |
| 10 | Data extraction process | Methods | [ ] |
| 11 | Data items sought | Methods | [ ] |
| 12 | Risk of bias assessment methods | Methods | [ ] |
| 13 | Summary measures (RR, MD, OR, etc.) | Methods | [ ] |
| 14 | Methods of synthesis | Methods | [ ] |
| 15 | Risk of bias across studies (publication bias) | Methods | [ ] |
| 16 | Additional analyses (sensitivity, subgroup, meta-regression) | Methods | [ ] |

### Results
| # | Item | Location | Done |
|---|------|----------|------|
| 17 | Study selection with PRISMA flow diagram | Results/Figure | [ ] |
| 18 | Study characteristics table | Results/Table | [ ] |
| 19 | Risk of bias within studies | Results | [ ] |
| 20 | Results of individual studies | Results/Forest plot | [ ] |
| 21 | Synthesis of results | Results | [ ] |
| 22 | Risk of bias across studies (publication bias results) | Results | [ ] |
| 23 | Additional analyses results | Results | [ ] |

### Discussion
| # | Item | Location | Done |
|---|------|----------|------|
| 24 | Summary of evidence | Discussion | [ ] |
| 25 | Limitations | Discussion | [ ] |
| 26 | Conclusions | Discussion | [ ] |

### Funding
| # | Item | Location | Done |
|---|------|----------|------|
| 27 | Sources of funding | Acknowledgments | [ ] |

---

## CARE Checklist (Case Reports)

### Title
| # | Item | Location | Done |
|---|------|----------|------|
| 1 | "Case report" in title with interesting findings | Title | [ ] |

### Abstract
| # | Item | Location | Done |
|---|------|----------|------|
| 2 | Key information: introduction, case presentation, conclusions | Abstract | [ ] |

### Introduction
| # | Item | Location | Done |
|---|------|----------|------|
| 3a | Scientific/clinical importance | Introduction | [ ] |
| 3b | Relevant medical literature briefly | Introduction | [ ] |

### Patient Information
| # | Item | Location | Done |
|---|------|----------|------|
| 4a | De-identified demographics | Case | [ ] |
| 4b | Chief complaints | Case | [ ] |
| 4c | Medical, surgical, family history | Case | [ ] |
| 4d | Relevant comorbidities | Case | [ ] |

### Clinical Findings
| # | Item | Location | Done |
|---|------|----------|------|
| 5 | Physical examination findings | Case | [ ] |

### Timeline
| # | Item | Location | Done |
|---|------|----------|------|
| 6 | Dates and times in table or figure | Case/Figure | [ ] |

### Diagnostic Assessment
| # | Item | Location | Done |
|---|------|----------|------|
| 7a | Diagnostic methods | Case | [ ] |
| 7b | Diagnostic challenges | Case | [ ] |
| 7c | Diagnostic reasoning | Case | [ ] |
| 7d | Prognostic characteristics | Case | [ ] |

### Therapeutic Intervention
| # | Item | Location | Done |
|---|------|----------|------|
| 8a | Types of intervention | Case | [ ] |
| 8b | Administration of intervention | Case | [ ] |
| 8c | Changes in intervention with rationale | Case | [ ] |

### Follow-up and Outcomes
| # | Item | Location | Done |
|---|------|----------|------|
| 9a | Clinician and patient-assessed outcomes | Case | [ ] |
| 9b | Important follow-up test results | Case | [ ] |
| 9c | Intervention adherence and tolerability | Case | [ ] |
| 9d | Adverse events | Case | [ ] |

### Discussion
| # | Item | Location | Done |
|---|------|----------|------|
| 10a | Discussion of findings | Discussion | [ ] |
| 10b | Relevant literature comparison | Discussion | [ ] |
| 10c | Conclusions with learning points | Discussion | [ ] |

### Patient Perspective
| # | Item | Location | Done |
|---|------|----------|------|
| 11 | Patient perspective shared (when appropriate) | Case/Discussion | [ ] |

### Informed Consent
| # | Item | Location | Done |
|---|------|----------|------|
| 12 | Informed consent statement | Methods/Acknowledgments | [ ] |

---

## Additional Checklists Reference

### STARD (Diagnostic Accuracy Studies)
- 30 items covering participants, test methods, analysis, results
- Required for diagnostic test validation studies
- Download: www.equator-network.org/reporting-guidelines/stard

### SPIRIT (Clinical Trial Protocols)
- 33 items for protocol development
- Required before trial registration
- Download: www.spirit-statement.org

### MOOSE (Meta-analyses of Observational Studies)
- Specific for observational study meta-analyses
- Additional items beyond PRISMA
- Download: www.equator-network.org/reporting-guidelines/meta-analysis-of-observational-studies-in-epidemiology-a-proposal-for-reporting-moose-group

### TRIPOD (Prediction Model Studies)
- 22 items for development/validation studies
- Required for clinical prediction models
- Download: www.tripod-statement.org

### CHEERS (Economic Evaluations)
- 24 items for cost-effectiveness studies
- Required for health economic analyses
- Download: www.equator-network.org/reporting-guidelines/cheers

---

## General Submission Checklist

### Pre-submission Requirements
- [ ] All co-authors reviewed and approved
- [ ] Corresponding author information complete
- [ ] ORCID IDs for all authors (if required)
- [ ] Conflict of interest statements from all authors
- [ ] Funding disclosure complete
- [ ] Author contributions defined

### Manuscript Components
- [ ] Cover letter prepared
- [ ] Title page with all required information
- [ ] Blinded manuscript (if required)
- [ ] Abstract within word limit
- [ ] Main text within word limit
- [ ] References in correct format
- [ ] Tables in correct format (Word/Excel)
- [ ] Figures in high resolution (300+ dpi)
- [ ] Figure legends complete
- [ ] Supplementary materials prepared

### Journal-Specific
- [ ] Target journal guidelines reviewed
- [ ] Manuscript formatted per journal style
- [ ] Reference style matches journal
- [ ] Required statements included (ethics, consent, data availability)
- [ ] Suggested reviewers listed (if required)
- [ ] Excluded reviewers listed (if applicable)
- [ ] Key words selected per journal requirements

### Final Verification
- [ ] All QC rounds completed (see qc_guide.md)
- [ ] Numbers verified across all sections
- [ ] All references verified
- [ ] Spell check completed
- [ ] Read aloud for flow
- [ ] Co-author final approval obtained
